Inogen (NASDAQ:INGN) Cut to Hold at StockNews.com

StockNews.com lowered shares of Inogen (NASDAQ:INGN) from a buy rating to a hold rating in a research report sent to investors on Thursday morning.

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research note on Friday, November 8th.

Inogen Stock Up 1.8 %

Shares of INGN stock opened at $9.38 on Thursday. The firm has a market capitalization of $223.43 million, a PE ratio of -4.17 and a beta of 1.04. The company has a 50 day moving average price of $9.62 and a 200-day moving average price of $9.60. Inogen has a 52 week low of $4.93 and a 52 week high of $13.33.

Institutional Investors Weigh In On Inogen

Large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of Inogen in the 3rd quarter worth approximately $111,000. Barclays PLC increased its holdings in Inogen by 72.9% during the third quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock valued at $539,000 after buying an additional 23,398 shares during the last quarter. Geode Capital Management LLC raised its position in Inogen by 1.1% in the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock worth $5,377,000 after acquiring an additional 5,921 shares during the period. State Street Corp boosted its stake in shares of Inogen by 2.8% during the 3rd quarter. State Street Corp now owns 511,018 shares of the medical technology company’s stock worth $4,957,000 after acquiring an additional 14,054 shares during the last quarter. Finally, Quarry LP bought a new stake in shares of Inogen during the 3rd quarter valued at $59,000. 89.94% of the stock is currently owned by institutional investors.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.